

ABSTRACT TEMPLATE for Company Presentations

The maximum number of words for this abstract is 300 words.

You may delete the section instructions, leaving only the bolded bullet title.

Questions for categories: Biotech/Pharma or Medical Devices or Health IT/Digital or Bio Food or Bio Convergence

Answers should not exceed 60 words per question

- **Investment Rational**
Outcomes in cancer treatment are dramatically improved by Next Generation Sequencing (NGS), but this has been unattainable for small and medium-size clinical laboratories without a genomic center. Foresee Genomics provides a sample preparation kit, molecular biology combined with a powerful, proprietary bioinformatic software, allowing these laboratories to use NGS. This market is estimated to be over \$20B and rapidly growing.
- **Business Strategy**
Foresee Genomics offers a molecular biology kit, combined with a bioinformatic software, which enables small to medium-size clinical oncology labs to sequence relevant genes in-house. Laboratories that will use Foresee Genomics's product can claim reimbursement and generate a revenue stream, give better treatment, and reduce turnaround time and maintain patients.
- **Core Technology**
Foresee Genomics developed a platform, a combination of proprietary molecular biology preparation and bioinformatics, which make the nanopore sequencing technology relevant in clinical cancer diagnostics. It addresses genomic panels relevant for a specific disease, giving the physician all actionable answers for precision treatment. Foresee Genomics allows any basic laboratory to do cutting edge NGS diagnostics with minimum capital investment.
- **Product Profile/Pipeline**
Currently, Foresee Genomics offers a kit for detecting mutations in myeloproliferative neoplasia, chronic lymphoblastic leukemia and carcinoma. More products are under development. The company is highly differentiated by having both molecular biology and software components and using the super affordable nanopore sequencer.
- **What's Next?**
Foresee Genomics continues to develop more products while looking to expand our pilot sites to the US. When pilots completed, we intend to start sales in the second half of 2023. Foresee Genomics is raising \$5M that will take us through R&D, regulation, and into sales.